Rockville, Maryland-based biopharmaceutical company, Supernus Pharmaceuticals, Inc. has been actively focusing on research and development, as well as commercialization of innovative products for the treatment of central nervous system (CNS) diseases. Its product portfolio includes Trokendi XR, an extended-release product and Oxtellar XR, an extended-release oxcarbazepine, which are used for the treatment of epilepsy and migraine headaches, and partial onset epilepsy seizures in adults and children, respectively. Additionally, the company specializes in Qelbree, a novel non-stimulant product used for treating attention-deficit hyperactivity disorder (ADHD) in both adults and pediatric patients. Furthermore, it markets APOKYN for acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO which is formulated to treat levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for treating cervical dystonia and sialorrhea; GOCOVRI for dyskinesia treatment in patients with PD; and Osmolex ER used for treating Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. The company also has several product candidates in its pipeline, including SPN-830 for treating off episodes in PD patients, SPN-817 for treating severe epilepsy, and SPN-820 for resistant depression. The company operates through pharmaceutical wholesalers, specialty pharmacies, and distributors, and was incorporated in 2005.